FDA Greenlights New Pet and Livestock Medicines
Published Date: 7/7/2026
Rule
Summary
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
New cattle fluralaner: use limits and residues
The FDA conditionally approved a fluralaner product for cattle (EXZOLT CATTLE‑CA) and added detailed use limits: dose 2.5 mg/kg, cattle must not be slaughtered for human consumption within 98 days of treatment (but if continuously exposed to temperatures >= 60°F after dosing they may be slaughtered 44 days after treatment), and the drug is not for use in female dairy cattle 20 months of age or older. The rule also sets fluralaner residue tolerances in cattle liver at 500 ppb and muscle at 350 ppb. These changes are effective July 7, 2026.
Multiple new/generic pet drug approvals
During January–March 2026 the FDA approved multiple new or generic animal drugs for companion animals (examples include maropitant chewables, firocoxib tablets for horses, robenacoxib injectable, atipamezole injection, potassium bromide chewable tablets for dogs, and a new atinvicitinib tablet). These approvals give veterinarians and pet caretakers additional approved medicines and take effect July 7, 2026.
Voluntary withdrawals remove some marketed products
FDA recorded voluntary withdrawals of approval for several products (e.g., ROMPUN 20 mg/mL; certain butorphanol and topical gentamicin/betamethasone products; Miconosol; TRI-OCTIC Ointment) on February 27, 2026 because they are no longer marketed. These regulatory entries reflect that those specific products are no longer approved for marketing as of the rule effective date July 7, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13492 — Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has confirmed that vasopressin in sodium chloride (0.9%, injection) wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules, helping patients and healthcare providers get more options. No changes in price or availability are expected right now, but more generics could be coming soon!
Previous / Next Documents
Previous: 2026-13715 — Performance Appraisal for General Schedule, Prevailing Rate, and Certain Other Employees
Starting August 6, 2026, federal employees like General Schedule and prevailing rate workers will see a smoother, fairer performance review process. The new rules cut out confusing rating steps, stop forced rating curves, and require supervisors to be held accountable. Agencies must also prove every two years that their appraisal systems work well, with some changes kicking in by January 1, 2027—making performance reviews clearer and more honest without extra hassle or cost.
Next: 2026-13717 — General Conference Committee of the National Poultry Improvement Plan and 47th Biennial Conference
The National Poultry Improvement Plan’s General Conference Committee is meeting August 11-14, 2026, in Salt Lake City to discuss important poultry health updates like new tests and disease news. This affects poultry farmers, state agencies, and industry folks who rely on these rules to keep flocks safe and healthy. No big costs are announced, but staying informed helps everyone protect their birds and business.